June 5, 2017June 5, 2017

Sophiris to Begin Dosing Patients in Phase 2b Study of Topsalysin for Prostate Cancer

News

Sophiris Bio has received a green light to begin dosing patients in a Phase 2b U.S. clinical trial of topsalysin (PRX302) for prostate cancer. The go-ahead was in the form of a Federal ... Read more

May 22, 2017May 22, 2017

Topsalysin Seen to Help Some Localized Prostate Cancer Patients in Small Study

News

Some patients with localized prostate cancer were seen to benefit from treatment with topsalysin (PRX302) in a small Phase 2a proof-of-concept trial (NCT02499848), according to Sophiris Bio. Findings from the trial ... Read more